Daily Cardiology Research Analysis
Analyzed 196 papers and selected 3 impactful papers.
Summary
Biodegradable structural heart technology, leadless pacing strategies after TAVR, and longitudinal LVEF trajectories after MI stood out. A multicenter RCT showed a scaffold‑degradable ASD occluder achieved 100% closure at 6 and 12 months; a meta‑analysis suggested leadless pacemakers after TAVR reduce device‑related complications; and a large binational cohort linked LVEF recovery and decline patterns to long‑term HF hospitalization and mortality.
Research Themes
- Biodegradable structural heart devices
- Leadless pacing after TAVR
- Post-MI LVEF trajectory and outcomes
Selected Articles
1. A scaffold-degradable single-rivet ASD occluder with amplatzer-like design: a multicenter randomized controlled trial.
In a multicenter RCT of 112 ASD patients (adult and pediatric), a biodegradable polydioxanone-based occluder achieved 100% closure at 6 and 12 months, matching metal controls, with one explant for tissue hyperplasia and histology showing near-complete scaffold degradation and endothelialization. No residual shunts >5 mm were observed at any time point.
Impact: First randomized, multicenter evidence that a scaffold‑degradable ASD device can match metal occluders in short‑term efficacy with histologic integration, potentially mitigating long‑term metal‑related complications.
Clinical Implications: If longer-term durability and safety are confirmed, biodegradable ASD occluders could reduce late erosion, thrombus, and imaging artifacts, influencing device selection—especially in younger patients where lifelong device presence matters.
Key Findings
- Randomized multicenter RCT with 112 implantations (57 biodegradable vs 55 metal) reported 100% closure at 6 months in both groups.
- At 12 months (n=109 followed), closure remained 100% in both groups; no residual shunt >5 mm at any time.
- One biodegradable device was explanted at 10 months for abnormal tissue hyperplasia; pathology showed near-complete PDO degradation with smooth endothelial coverage.
- Baseline defects were smaller in the biodegradable arm (8.48 ± 2.86 mm) than control (10.41 ± 5.21 mm).
Methodological Strengths
- Prospective multicenter randomized controlled design
- Pathology-confirmed scaffold degradation and endothelialization
Limitations
- Modest sample size and 12-month follow-up limit durability assessment
- Imbalance in baseline defect size may favor outcomes in the experimental arm
Future Directions: Conduct larger, longer (3–5+ years) RCTs with core-lab adjudication to evaluate late erosion, arrhythmias, endocarditis, thrombus, and MRI artifact, and to assess outcomes in larger defects.
Metallic atrial septal defect (ASD) occluders are associated with various mid- to long-term complications. To address this, our team developed a novel biodegradable Pansy ASD occluder, and this multicenter RCT aimed to evaluate its effectiveness and safety. A prospective, multicenter, randomized controlled trial was carried out on adult and pediatric patients using the Pansy occluder with a biodegradable polydioxanone (PDO) framework. The primary efficacy endpoint of this clinical trial is the closure success rate at six months post-operation. From May 2021 to March 2023, a total of 127 patients were screened across seven research centers, with 112 patients (including 71 pediatric patients; 57 to the experimental group, 55 to the metal occluder control group) ultimately underwent occluder implantation. In these patients, the average defect size was 8.48 ± 2.86 mm in the experimental group and 10.41 ± 5.21 mm in the control group. The closure success rate at six months post-operation was 100% for both groups, and no residual shunt greater than 5 mm was detected at any follow-up time point. In the experimental group, one patient required device explantation at 10 months postoperatively due to abnormal tissue hyperplasia. Pathological analysis confirmed near-complete degradation of the PDO framework with smooth endothelial coverage. A total of 109 patients completed the 12-month post-operative follow-up, with both groups again demonstrating a closure success rate of 100%. The Pansy occluder shows promising safety and efficacy outcomes at 12 months, though longer-term data are needed to confirm durability.
2. Left Ventricular Ejection Fraction Trajectory and Long-Term Outcomes Following Percutaneous Coronary Intervention for Myocardial Infarction.
In 13,439 post‑MI PCI patients with serial echocardiograms, LVEF trajectories strongly stratified risk: persistently reduced and newly declining LVEF carried the highest hazards, while even recovered LVEF had higher HF hospitalization and mortality than persistently preserved LVEF. Findings underscore trajectory‑based risk beyond single LVEF values.
Impact: Provides large-scale, contemporary evidence that post‑MI management should consider LVEF trajectory rather than a single measurement to guide intensity of GDMT, imaging, and follow‑up.
Clinical Implications: Patients with recovered or declining LVEF after MI may warrant intensified GDMT, closer surveillance, and early HF management strategies despite apparent EF improvement.
Key Findings
- LVEF trajectory groups (redEF 28.2%, recEF 14.8%, pEF 53.0%, decEF 3.9%) showed graded risks for HF hospitalization and mortality.
- Compared with pEF, adjusted HRs for HF hospitalization were 8.49 (redEF), 5.74 (decEF), and 3.18 (recEF).
- Adjusted mortality HRs vs pEF were 2.20 (redEF), 2.10 (decEF), and 1.30 (recEF).
- Even LVEF recovery did not normalize risk to pEF levels.
Methodological Strengths
- Very large binational cohort with serial echocardiography
- Adjusted time-to-event analyses across clinically relevant endpoints
Limitations
- Observational design with potential residual confounding and selection bias
- Heterogeneity in imaging timing and protocols across registries
Future Directions: Prospective studies to test whether trajectory‑guided intensification of GDMT and surveillance reduces HF events; integration with biomarkers and imaging fibrosis markers.
BACKGROUND: Data are lacking on left ventricular ejection fraction (LVEF) trajectory following myocardial infarction (MI). OBJECTIVES: This study aimed to evaluate the impact of LVEF trajectory after percutaneous coronary intervention (PCI) for MI on long-term outcomes. METHODS: Patients undergoing PCI for MI (2007-2022) with serial echocardiograms were identified in the Swedish Coronary Angiography and Angioplasty Registry and the UC San Diego internal National Cardiovascular Data Registry CathPCI Registry. All-cause mortality and heart failure hospitalization within 6 years were assessed with time-to-event analysis adjusted for baseline characteristics. RESULTS: Of 13,439 patients (mean age 64 ± 10 years, 24.5% female, 46.8% ST-segment elevation MI), 28.2% had consistently reduced LVEF (redEF), 14.8% recovered their LVEF (recEF), 53.0% had consistently preserved LVEF (pEF), and 3.9% decreased from preserved to reduced LVEF (decEF). Heart failure hospitalization rates were 40.0% for redEF, 30.4% for decEF, 16.1% for recEF, and 6.4% for pEF (P < 0.001). Compared to pEF, the heart failure hospitalization risk was significantly higher for redEF (adjusted HR [aHR]: 8.49; 95% CI: 7.49-9.64; P < 0.001), decEF (aHR: 5.74; 95% CI: 4.69-7.02; P < 0.001), and recEF (aHR: 3.18; 95% CI: 2.70-3.76; P < 0.001). Mortality rates were 14.0% for redEF, 14.9% for decEF, 7.8% for recEF, and 6.7% for pEF (P < 0.001). Compared to pEF, the mortality risk was significantly higher for redEF (aHR: 2.20; 95% CI: 1.86-2.59; P < 0.001), decEF (aHR: 2.10; 95% CI: 1.56-2.82; P < 0.001), and recEF (aHR: 1.30; 95% CI: 1.02-1.65; P = 0.032). CONCLUSIONS: LVEF trajectory after MI significantly impacts long-term outcomes. Even patients with LVEF recovery remain at increased risk for heart failure hospitalization and mortality compared to those with pEF.
3. Leadless Pacemaker in Bradyarrhythmia After Transcatheter Aortic Valve Replacement: A Meta-Analysis.
Across 11 studies (n=11,750) of post‑TAVR pacing, leadless systems showed significantly fewer device‑related complications (none reported; aHR 0.35 vs TPM) with no device‑related deaths and comparable all‑cause mortality and HF hospitalization. Procedural metrics were similar, supporting feasibility.
Impact: Synthesizes emerging evidence that LPMs may offer a safer post‑TAVR pacing strategy without sacrificing efficacy, informing device selection in a rapidly growing population.
Clinical Implications: For TAVR patients requiring pacemakers, LPMs may reduce device‑related complications and eliminate lead/pocket issues; selection should consider anatomy, pacing needs (e.g., AV synchrony), and operator expertise.
Key Findings
- No device-related complications were reported in LPM cohorts; device-related complications were significantly lower vs TPM (aHR 0.35, 95% CI 0.13–0.97).
- No device-related mortality with LPM; all-cause mortality and HF hospitalization were similar between LPM and TPM.
- Procedural feasibility was comparable: similar procedure time, fluoroscopy time, and hospital length of stay.
Methodological Strengths
- Systematic search with pooled adjusted estimates across multiple endpoints
- Large aggregate sample of TAVR recipients enhances generalizability
Limitations
- Predominantly observational studies with potential confounding by indication
- Follow-up durations and outcome definitions varied across studies
Future Directions: Prospective randomized trials comparing LPM vs TPM in post‑TAVR populations, with cost‑effectiveness, pacing‑dependence, AV synchrony, and long‑term leadless device management pathways.
Leadless pacemaker (LPM) offers a favorable safety profile for bradyarrhythmia, especially in patients at high risk for infection from transvenous pacemaker (TPM). However, its use for bradyarrhythmia after transcatheter aortic valve replacement (TAVR) remains unexplored. We conducted a systematic search from the inception of PubMed to November 2025. Eligible studies included adults who received a pacemaker after TAVR. Primary endpoints were overall complications and device-related complications. Secondary endpoints included all-cause mortality, device-related mortality, hospitalization for heart failure, procedure time, fluoroscopy time, and length of stay after pacemaker implantation. We included a total of 11 studies involving 11,750 patients who underwent TAVR (1243 with LPM and 10,507 with TPM). None of the patients in the LPM group experienced device-related complications, with significantly lower rates compared to the TPM group [adjusted hazard ratio (aHR) 0.35, 95% confidence interval (CI): 0.13-0.97; I2 = 0%]. Similarly, no device-related mortality was observed in the LPM group. All-cause mortality and hospitalization for heart failure were comparable between the LPM and TPM groups (aHR 1.02, 95% CI, 0.05-20.68; I2 = 25% and aHR 0.87, 95% CI, 0.24-3.17; I2 = 0%, respectively). The feasibility of LPM was also similar to TPM in terms of procedural time (MD -28.66 minutes, 95% CI, -92.36 to 35.03; I2 = 11%), fluoroscopy time (MD -1.36 minutes, 95% CI, -6.30 to 3.59; I2 = 0%), and length of stay (MD -0.53 days, 95% CI, -1.33 to 0.27; I2 = 6%). In conclusion, LPM could serve as a first-line pacing strategy in bradyarrhythmia post-TAVR due to its safer profile with comparable efficacy and feasibility to TPM.